Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 2/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.64 |
| ▸ | SNCA | P37840 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184306 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL10936176 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL10936173 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7736120 | 0.86 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL8209314 | 0.86 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7736116 | 0.86 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL23743976 | 0.86 | CYP19A1 (0.80) | CYP19A1 | |
| SCHEMBL3366207 | 0.86 | CYP19A1 (0.78) | CYP19A1 | |
| SCHEMBL3366201 | 0.86 | CYP19A1 (0.78) | CYP19A1 | |
| SCHEMBL11022288 | 0.86 | CYP19A1 (0.74) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712968-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | Crinetics Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4511660-A1 | PROVISION OF A MEDICAL RISK ASSESSMENT FOR NONCLASSICAL 21-HYDROXYLASE DEFICIENCY | SORBONNE UNIVERSITE (FR) | 2025-02-26 | — | — | EP | claimed |
| WO-2024242979-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | Crinetics Pharmaceuticals, Inc. (US) | 2024-11-28 | — | — | WO | claimed |
| CN-116322544-B | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2023203284-A1 | PROVISION OF A MEDICAL RISK ASSESSMENT FOR NONCLASSICAL 21-HYDROXYLASE DEFICIENCY | SORBONNE UNIVERSITE (FR) | 2023-10-26 | — | — | WO | claimed |
| EP-4264281-A2 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | F. Hoffmann-La Roche AG (CH) | 2023-10-25 | — | — | EP | claimed |
| CN-113621521-B | A culture method of Monascus with antioxidant and antiinflammatory effects and with effect of promoting cholesterol inhibitor production | 厦门医学院 | 2023-09-29 | — | — | CN | claimed |
| CN-113789362-B | Method for synthesizing 16 alpha-hydroxylated steroid compound by using cytochrome P450 enzyme | 浙江理工大学 | 2023-09-08 | — | — | CN | claimed |
| CN-116322544-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2023-06-23 | — | — | CN | claimed |
| EP-4175572-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2004058048-A2 | DEHYDROEPIANDROSTERONE (DHEA) CONGENERS FOR PREVENTION AND/OR TREATMENT OF ULCERS | INFLABLOC PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1352054-A2 | ASPERGILLUS OCHRACEUS 11 ALPHA HYDROLASE AND OXIDOREDUCTASE | Pharmacia Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030148420-A1 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | claimed |
| US-6468981-B1 | COMPOUND COMPRISING STEROID MOIETY WHICH BINDS TO ANDROGEN RECEPTOR COVALENTLY LINKED TO POLYCATIONIC SALT COMPLEXED WITH NUCLEIC ACID CAPABLE OF THERAPEUTICALLY MODIFYING OR REVEALING PRESENCE OF ANDROGEN RECEPTOR-CONTAINING CELL | EMORY UNIVERSITY | 2002-10-22 | — | — | US | claimed |
| WO-2002046386-A2 | ASPERGILLUS OCHRACEUS 11 ALPHA HYDROXYLASE AND OXIDOREDUCTASE | PHARMACIA CORPORATION (US) | 2002-06-13 | — | — | WO | claimed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| EP-0773719-A4 | COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGEN RECEPTORS | UNIV EMORY (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0773719-A1 | COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGEN RECEPTORS | EMORY UNIVERSITY (US) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003875-A1 | COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGEN RECEPTORS | EMORY UNIVERSITY (US) | 1996-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148420-A1 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase | CYP21A2, CYP11B1, CYP17A1 | CYP19A1 21/4885ALDH1A1 167/4885LMNA 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.